187 related articles for article (PubMed ID: 31971569)
1. Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia.
Barz MJ; Hof J; Groeneveld-Krentz S; Loh JW; Szymansky A; Astrahantseff K; von Stackelberg A; Khiabanian H; Ferrando AA; Eckert C; Kirschner-Schwabe R
Blood; 2020 Mar; 135(12):921-933. PubMed ID: 31971569
[TBL] [Abstract][Full Text] [Related]
2. Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia.
Meyer JA; Wang J; Hogan LE; Yang JJ; Dandekar S; Patel JP; Tang Z; Zumbo P; Li S; Zavadil J; Levine RL; Cardozo T; Hunger SP; Raetz EA; Evans WE; Morrison DJ; Mason CE; Carroll WL
Nat Genet; 2013 Mar; 45(3):290-4. PubMed ID: 23377183
[TBL] [Abstract][Full Text] [Related]
3. Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia.
Tzoneva G; Dieck CL; Oshima K; Ambesi-Impiombato A; Sánchez-Martín M; Madubata CJ; Khiabanian H; Yu J; Waanders E; Iacobucci I; Sulis ML; Kato M; Koh K; Paganin M; Basso G; Gastier-Foster JM; Loh ML; Kirschner-Schwabe R; Mullighan CG; Rabadan R; Ferrando AA
Nature; 2018 Jan; 553(7689):511-514. PubMed ID: 29342136
[TBL] [Abstract][Full Text] [Related]
4. Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.
Tzoneva G; Perez-Garcia A; Carpenter Z; Khiabanian H; Tosello V; Allegretta M; Paietta E; Racevskis J; Rowe JM; Tallman MS; Paganin M; Basso G; Hof J; Kirschner-Schwabe R; Palomero T; Rabadan R; Ferrando A
Nat Med; 2013 Mar; 19(3):368-71. PubMed ID: 23377281
[TBL] [Abstract][Full Text] [Related]
5. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia.
Li B; Brady SW; Ma X; Shen S; Zhang Y; Li Y; Szlachta K; Dong L; Liu Y; Yang F; Wang N; Flasch DA; Myers MA; Mulder HL; Ding L; Liu Y; Tian L; Hagiwara K; Xu K; Zhou X; Sioson E; Wang T; Yang L; Zhao J; Zhang H; Shao Y; Sun H; Sun L; Cai J; Sun HY; Lin TN; Du L; Li H; Rusch M; Edmonson MN; Easton J; Zhu X; Zhang J; Cheng C; Raphael BJ; Tang J; Downing JR; Alexandrov LB; Zhou BS; Pui CH; Yang JJ; Zhang J
Blood; 2020 Jan; 135(1):41-55. PubMed ID: 31697823
[TBL] [Abstract][Full Text] [Related]
6. NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia.
Tulstrup M; Grosjean M; Nielsen SN; Grell K; Wolthers BO; Wegener PS; Jonsson OG; Lund B; Harila-Saari A; Abrahamsson J; Vaitkeviciene G; Pruunsild K; Toft N; Holm M; Hulegårdh E; Liestøl S; Griskevicius L; Punab M; Wang J; Carroll WL; Zhang Z; Dalgaard MD; Gupta R; Nersting J; Schmiegelow K
Leukemia; 2018 Dec; 32(12):2527-2535. PubMed ID: 30201983
[TBL] [Abstract][Full Text] [Related]
7. Relapsed acute lymphoblastic leukemia-specific mutations in NT5C2 cluster into hotspots driving intersubunit stimulation.
Hnízda A; Fábry M; Moriyama T; Pachl P; Kugler M; Brinsa V; Ascher DB; Carroll WL; Novák P; Žaliová M; Trka J; Řezáčová P; Yang JJ; Veverka V
Leukemia; 2018 Jun; 32(6):1393-1403. PubMed ID: 29535428
[TBL] [Abstract][Full Text] [Related]
8. Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia.
Dieck CL; Tzoneva G; Forouhar F; Carpenter Z; Ambesi-Impiombato A; Sánchez-Martín M; Kirschner-Schwabe R; Lew S; Seetharaman J; Tong L; Ferrando AA
Cancer Cell; 2018 Jul; 34(1):136-147.e6. PubMed ID: 29990496
[TBL] [Abstract][Full Text] [Related]
9. CRISPR/Cas9-Mediated Induction of Relapse-Specific
Nguyen TTT; Tanaka Y; Sanada M; Hosaka M; Tamai M; Kagami K; Komatsu C; Somazu S; Harama D; Kasai S; Watanabe A; Akahane K; Goi K; Inukai T
Mol Pharmacol; 2023 Apr; 103(4):199-210. PubMed ID: 36669880
[TBL] [Abstract][Full Text] [Related]
10. Pharmacologic Inhibition of NT5C2 Reverses Genetic and Nongenetic Drivers of 6-MP Resistance in Acute Lymphoblastic Leukemia.
Reglero C; Dieck CL; Zask A; Forouhar F; Laurent AP; Lin WW; Albero R; Miller HI; Ma C; Gastier-Foster JM; Loh ML; Tong L; Stockwell BR; Palomero T; Ferrando AA
Cancer Discov; 2022 Nov; 12(11):2646-2665. PubMed ID: 35984649
[TBL] [Abstract][Full Text] [Related]
11. Genetics and mechanisms of NT5C2-driven chemotherapy resistance in relapsed ALL.
Dieck CL; Ferrando A
Blood; 2019 May; 133(21):2263-2268. PubMed ID: 30910786
[TBL] [Abstract][Full Text] [Related]
12. Screening for gene mutations: will identification of NT5C2 mutations help predict the chance of relapse in acute lymphoblastic leukemia?
Meyer JA; Carroll WL; Bhatla T
Expert Rev Hematol; 2013 Jun; 6(3):223-4. PubMed ID: 23782074
[No Abstract] [Full Text] [Related]
13. Multiclonal complexity of pediatric acute lymphoblastic leukemia and the prognostic relevance of subclonal mutations.
Antić Ž; Yu J; Van Reijmersdal SV; Van Dijk A; Dekker L; Segerink WH; Sonneveld E; Fiocco M; Pieters R; Hoogerbrugge PM; Van Leeuwen FN; Van Kessel AG; Waanders E; Kuiper RP
Haematologica; 2021 Dec; 106(12):3046-3055. PubMed ID: 33147938
[TBL] [Abstract][Full Text] [Related]
14. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia.
Ma X; Edmonson M; Yergeau D; Muzny DM; Hampton OA; Rusch M; Song G; Easton J; Harvey RC; Wheeler DA; Ma J; Doddapaneni H; Vadodaria B; Wu G; Nagahawatte P; Carroll WL; Chen IM; Gastier-Foster JM; Relling MV; Smith MA; Devidas M; Guidry Auvil JM; Downing JR; Loh ML; Willman CL; Gerhard DS; Mullighan CG; Hunger SP; Zhang J
Nat Commun; 2015 Mar; 6():6604. PubMed ID: 25790293
[TBL] [Abstract][Full Text] [Related]
15. FPGS relapse-specific mutations in relapsed childhood acute lymphoblastic leukemia.
Yu SL; Zhang H; Ho BC; Yu CH; Chang CC; Hsu YC; Ni YL; Lin KH; Jou ST; Lu MY; Chen SH; Wu KH; Wang SC; Chang HH; Pui CH; Yang JJ; Zhang J; Lin DT; Lin SW; Ma X; Yang YL
Sci Rep; 2020 Jul; 10(1):12074. PubMed ID: 32694622
[TBL] [Abstract][Full Text] [Related]
16. Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes.
Lindqvist CM; Lundmark A; Nordlund J; Freyhult E; Ekman D; Carlsson Almlöf J; Raine A; Övernäs E; Abrahamsson J; Frost BM; Grandér D; Heyman M; Palle J; Forestier E; Lönnerholm G; Berglund EC; Syvänen AC
Oncotarget; 2016 Sep; 7(39):64071-64088. PubMed ID: 27590521
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90.
Tallen G; Ratei R; Mann G; Kaspers G; Niggli F; Karachunsky A; Ebell W; Escherich G; Schrappe M; Klingebiel T; Fengler R; Henze G; von Stackelberg A
J Clin Oncol; 2010 May; 28(14):2339-47. PubMed ID: 20385996
[TBL] [Abstract][Full Text] [Related]
18. NUDT15 polymorphism and NT5C2 and PRPS1 mutations influence thiopurine sensitivity in acute lymphoblastic leukaemia cells.
Somazu S; Tanaka Y; Tamai M; Watanabe A; Kagami K; Abe M; Harama D; Shinohara T; Akahane K; Goi K; Sugita K; Moriyama T; Yang J; Goto H; Minegishi M; Iwamoto S; Takita J; Inukai T
J Cell Mol Med; 2021 Nov; 25(22):10521-10533. PubMed ID: 34636169
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL-protocols: results of the German Cooperative Study.
Dopfer R; Henze G; Bender-Götze C; Ebell W; Ehninger G; Friedrich W; Gadner H; Klingebiel T; Peters C; Riehm H
Blood; 1991 Nov; 78(10):2780-4. PubMed ID: 1824271
[TBL] [Abstract][Full Text] [Related]
20. Effects of NT5C2 Germline Variants on 6-Mecaptopurine Metabolism in Children With Acute Lymphoblastic Leukemia.
Jiang C; Yang W; Moriyama T; Liu C; Smith C; Yang W; Qian M; Li Z; Tulstrup M; Schmiegelow K; Crews KR; Zhang H; Pui CH; Evans W; Relling M; Bhatia S; Yang JJ
Clin Pharmacol Ther; 2021 Jun; 109(6):1538-1545. PubMed ID: 33124053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
